Compare Amylx Pharmaceuticals Inc (AMLX) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs IQIYI Inc - ADR — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while IQIYI Inc - ADR trades at $1.33 (market cap $1.30B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 2× IQIYI Inc - ADR's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| AMLX | IQ | |
|---|---|---|
Market Cap | $2.64B | $1.30B |
Sector | Health | Media |
52-Week High | $24.19 | $2.79 |
52-Week Low | $7.82 | $0.96 |
Enterprise Value | $2.39B | $2.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
IQ trades at $1.325, down 2.57% in 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $206.31 million in 2025, with revenue declining to $27.29 billion, though it beat EPS expectations in two recent quarters. Analyst sentiment is mixed with a 50% buy rating, while news highlights AI platform growth and leadership changes as potential catalysts.
The outlook hinges on IQ's AI-driven content strategy and cost management reversing profitability declines. Risks include intense competition, regulatory pressures in China, and sustained negative cash flow projections for 2026. Upside potential exists if execution improves, but high debt and margin pressures warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
